Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Therapeutic Index01:13

Therapeutic Index

7.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Assessment of apical radial pulse01:25

Assessment of apical radial pulse

1.4K
Apical-Radial (A-R) Pulse Assessment
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel approach to teaching empathic leadership using heuristics.

BMJ leader·2026
Same author

Comparing structured note-taking and multiple-choice question writing as learning strategies among physiotherapy students.

BMC medical education·2025
Same author

Global research partnerships and the impact of inequitable research practices on systematic reviews.

BMJ global health·2025
Same author

The 6 Minute Walk Test as a predictor of mortality in idiopathic pulmonary fibrosis: A systematic review.

Respiratory investigation·2025
Same author

Associations Between Lactate Thresholds and 2000 m Rowing Ergometer Performance: Implications for Prediction-A Systematic Review.

Sports medicine - open·2025
Same author

Global survey on point-of-care ultrasound (pocus) use in child surgery.

Pediatric surgery international·2024
Same journal

Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets.

Vascular health and risk management·2026
Same journal

Association Between Apelin Gene -1860T>C (rs56204867) Polymorphism and Coronary Artery Disease in a Syrian Cohort.

Vascular health and risk management·2026
Same journal

Assessment of Blood Pressure Control Among Hypertensive Patients Attending Primary Healthcare Settings in Qatar: A Retrospective Chart Review.

Vascular health and risk management·2026
Same journal

Post-Stroke Aspiration Pneumonia in Riyadh, Saudi Arabia: A Retrospective Cohort Study.

Vascular health and risk management·2026
Same journal

CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHA<sub>2</sub>DS<sub>2</sub>-VA Scores as Predictors of Short- and Long-Term Mortality Following Transvenous Lead Extraction.

Vascular health and risk management·2026
Same journal

Serum Albumin Level Predicts Systemic Arterial Stiffening Mediated Partially by Change in Lean Body Mass: A Retrospective Cohort Study in General Japanese Population.

Vascular health and risk management·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Quick reference guide to apixaban.

Katherine Victoria Hurst1, John Matthew O'Callaghan1, Ashok Handa1

  • 1Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Vascular Health and Risk Management
|July 27, 2017
PubMed
Summary
This summary is machine-generated.

Direct oral anticoagulants like apixaban offer benefits for preventing stroke and venous thromboembolism (VTE). Clinical trials show apixaban is effective and safe for long-term anticoagulation therapy.

Keywords:
apixabanstroke managementvenous thromboembolism

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.2K

Related Experiment Videos

Last Updated: Feb 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.2K

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Direct oral anticoagulants (DOACs) are increasingly prescribed for patients at risk of venous thromboembolism (VTE) and stroke.
  • DOACs offer advantages such as rapid onset, predictable anticoagulation, and no need for routine monitoring.
  • Apixaban, a selective factor Xa inhibitor, is approved for stroke prevention in nonvalvular atrial fibrillation and VTE management.

Purpose of the Study:

  • To review the clinical use of apixaban for preventing and treating thromboembolic diseases.
  • To highlight key study findings supporting apixaban's current indications and application.

Main Methods:

  • Review of multiple randomized controlled trials, including ARISTOTLE and AMPLIFY.
  • Analysis of data on apixaban's efficacy and safety compared to vitamin K antagonists.

Main Results:

  • Apixaban demonstrated non-inferiority to vitamin K antagonists in preventing stroke and VTE.
  • Apixaban exhibits a favorable safety profile in clinical studies.
  • The drug provides predictable anticoagulant effects with a rapid onset of action.

Conclusions:

  • Apixaban is a well-established DOAC for the prevention and treatment of thromboembolic disorders.
  • Evidence from major trials supports its efficacy and safety in clinical practice.
  • Apixaban offers a valuable therapeutic option for long-term anticoagulation.